Compare FedEx Corporation (FDX) vs Natera Inc. Common Stock (NTRA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
FedEx Corporation vs Natera Inc. Common Stock — how do they compare? FedEx Corporation trades at $291.96 (market cap $68.94B), while Natera Inc. Common Stock trades at $393.27 (market cap $57.03B). The key difference: FedEx Corporation is the larger of the two by market cap, and FedEx Corporation pays a 1.68% dividend while Natera Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold FedEx Corporation for 87 Days and Natera Inc. Common Stock for 0 Days on average.
| FDX | NTRA | |
|---|---|---|
Market Cap | $68.94B | $57.03B |
Volume | 1,120,376 | 1,131,157 |
Sector | Industrials | Health |
52-Week High | $339.35 | $425.64 |
52-Week Low | $189.87 | $179.42 |
Typical Hold Time | 87 Days | 0 Days |
Enterprise Value | $98.57B | $56.18B |
Dividend Yield | 1.68% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FedEx (FDX) trades at $290.59, down 0.56% on the day, with a bearish technical signal and mixed oscillators. The company shows stable profitability with a net income margin of 4.68% and a P/E of 15.67, while recent earnings beats and a $300 million electric truck order from Harbinger highlight operational momentum. Cash flow trends indicate a projected rebound in 2026 to $7.8 billion net cash flow.
The outlook is cautiously optimistic, supported by analyst consensus favoring Buy ratings (57%) and a $307.55 price target. Key risks include exposure to fuel price volatility and competitive pressures, but strong institutional backing and dividend payments provide stability for long-term investors.
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About FedEx Corporation
FedEx pioneered overnight delivery in 1973 and remains the world's largest express package provider. In its fiscal 2020 (ended May 2020), FedEx derived 51% of revenue from its express division, 33% from ground, and 10% from freight, its asset-based less-than-truckload shipping segment. The remainder comes from other services, including FedEx Office, which provides document production/shipping, and FedEx Logistics, which provides global forwarding. FedEx acquired Dutch parcel delivery firm TNT Express in 2016. TNT was previously the fourth-largest global parcel delivery provider.
Read more on FDX →About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →
